Triple combination therapy and zeaxanthin for the treatment of neovascular age-related macular degeneration: an interventional comparative study and cost-effectiveness analysis by R. Joseph Olk et al.
Olk et al. Int J Retin Vitr  (2015) 1:22 
DOI 10.1186/s40942-015-0019-2
ORIGINAL ARTICLE
Triple combination therapy 
and zeaxanthin for the treatment of neovascular 
age-related macular degeneration: 
an interventional comparative study 
and cost-effectiveness analysis
R. Joseph Olk1,2, Enrique Peralta1,2, Dennis L. Gierhart1,3, Gary C. Brown1,4* and Melissa M. Brown1,5
Abstract 
Background: Reports of triple combination therapy for neovascular age-related macular degeneration (AMD) sug-
gest a benefit, as do reports for zeaxanthin. An interventional comparative study was thus undertaken to evaluate the 
efficacy of triple combination therapy with and without zeaxanthin, as well as the economic viability of the therapies.
Methods: The cases of 543 consecutive eyes of 424 patients with subfoveal choroidal neovascularization (CNV) sec-
ondary to AMD were reviewed. All eyes were treated with triple combination therapy (triple therapy) consisting of: (1) 
reduced-fluence photodynamic therapy with verteporfin, (2) intravitreal bevacizumab and (3) intravitreal dexametha-
sone. Therapy was repeated as necessary. One cohort of patients was also given supplementation with 20 mg of oral 
zeaxanthin (Zx) daily.
Results: The triple therapy group without Zx received a mean of 2.8 treatment cycles and 87 % of patients had stable 
or improved vision at 24 months. In the triple therapy group with Zx, the mean number of treatment cycles was 2.1, 
with 83 % of patients having stable or improved vision at 24 months. At 24 months, CNV developed in 12.5 % of fellow 
eyes treated with triple therapy alone; CNV developed in 6.25 % of eyes treated with triple therapy with Zx (p = 0.03). 
An average cost-utility analysis revealed that triple therapy was cost-effective with a cost-utility ratio of $26,574/
QALY, while triple therapy with Zx was more cost-effective with an average cost-utility ratio of $19,962/QALY. The 
incremental cost-utility analysis assessing the addition of Zx to triple therapy disclosed Zx supplementation was very 
cost-effective at $5302/QALY. When it was assumed that triple therapy with Zx reduced fellow eye CNV development 
by 30.3 %, the incremental cost-utility dropped to (−$6332/QALY), indicating that adding Zx to triple therapy yielded 
greater patient value, and was also less expensive than using triple therapy alone.
Conclusions: Triple therapy is comparatively effective and cost-effective. Considerably less treatment is needed than 
reported in monotherapy studies. The addition of oral Zx appears to further reduce the treatment cycles required, and 
possibly reduce the risk of CNV development in the fellow eye.
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Background
Age-related macular degeneration (AMD) is the leading 
cause of vision loss in adults over age 50 [1, 2]. The most 
severe vision loss occurs from choroidal neovasculariza-
tion (CNV) destroying macular structure and function. 
Vascular endothelial growth factor A (VEGF-A) has been 
identified as promoting CNV [3–5]. Studies have also 
noted the inverse association between the xanthophyll 
carotenoid zeaxanthin (Zx) and AMD pathogenesis [6, 7].
Current treatment options for neovascular AMD are 
multiple, but each has deficiencies. Photodynamic ther-
apy with verteporfin (PDT) directly targets CNV. While 
it has been shown to be effective at selective destruction 
of vascular endothelial growth cells, the treatment incites 
an injured cell response that is counter-productive [8, 9].
Many studies have established anti-VEGF efficacy for 
CNV and AMD. The ANCHOR [10] and MARINA [11] 
studies demonstrated the benefit of monthly injections 
of ranibizumab, the CATT [12] study showed the equiva-
lency of bevacizumab and ranibizumab, and the PIER 
and PRONTO Studies [13] showed decreased frequency 
of treatment can still be effective. Overall cost and the 
burden of frequent injections, however, diminish satisfac-
tion with this therapy.
The presence of an inflammatory component to AMD 
is now well established [14]. Thus, there is also a ration-
ale for the use of corticosteroids for treating neovascular 
AMD [15, 16].
A limited number of studies have begun to evaluate the 
possible synergy created through a combination of the 
three treatment modalities: PDT, anti-VEGF therapy and 
corticosteroids [15, 16]. These studies seem to balance 
efficacy and treatment burden.
Major epidemiology studies [17–20] have shown that 
both higher dietary and serum levels of lutein and Zx are 
associated with significantly lower odds ratios of AMD. 
The AREDS Study Group [19] found higher dietary 
intakes of lutein and Zx reduced progression of both wet 
and dry AMD. The findings were so significant that the 
AREDS II was undertaken to study these specific effects.
In this study, we sought to further explore triple com-
bination therapy (triple therapy) potential for CNV, with 
the thought of reducing treatment burden at a reduced 
cost compared to monotherapy treatments. In addition, 
we investigated the added effect of oral Zx. This paper 
is NOT a randomized clinical trial, but rather an inter-
ventional comparative study of two cohorts of patients 
treated for neovacular AMD. One cohort was treated 
with triple therapy alone, the other with triple therapy 
plus oral Zx. Recognizing the limitations of an inter-
ventional comparative study, the investigation was also 
undertaken to assess whether a prospective, randomized, 
controlled trial should be considered.
Patients and methods
This comparative interventional study enrolled 424 
participants with 543 eyes with neovascular AMD. The 
consecutive triple therapy without Zx patients were 
treated initially. When the lead author discovered the 
theoretical benefits of oral Zx, this was added to triple 
therapy. Thus, the triple therapy with Zx cohort partic-
ipants were all enrolled after all of the cohort without 
Zx participants were already enrolled and had begun 
treatment.
Inclusion criteria Participants with classic, minimally 
classic, and/or occult subfoveal CNV were enrolled. Only 
eyes with macular blood, subretinal fluid, and/or retinal 
edema with characteristic CNV findings confirmed by 
fluorescein angiography, optical coherence tomography 
(OCT) or indocyanine green angiography were included.
Exclusion criteria Eyes with greater than 12 optic disc 
areas of CNV were excluded. Eyes with less than 20/400 
vision were also excluded. The presence of blood was not 
an exclusion feature unless it covered greater than 12 disc 
areas.
Demographic features Two hundred seventy-nine 
participants were female and 145 were male. The mean 
age was 80  years, with a range from 50 to 99  years. All 
patients were taking a multi-vitamin (usually Centrum 
Silver; Pfizer) and an AREDS I antioxidant regimen (usu-
ally PreserVision; Bausch & Lomb) during the trial.
Triple therapy patients without zeaxanthin In this 
group there were 290 eyes of 210 patients; 182 were 
female and 58 male, with an age range of 50–99 and a 
mean age of 82. Eighty patients presented with bilateral 
CNV and 130 patients had unilateral CNV. Two hundred 
sixty-one eyes (90  %) were followed for 12  months and 
206 eyes (71  %) for 24  months. Baseline visions ranged 
from 20/30 to 20/400, with a mean LogMAR visual acuity 
of 1.12 [20/250]. Patients received an intravitreal injec-
tion of 1.25 mg of bevacizumab at the initial visit, 1000 
micrograms of intravitreal dexamethasone within 1 week, 
and reduced-fluence (PDT), usually within 2 weeks from 
baseline. PDT therapy utilized 25 mJ for 83 s. This proto-
col constituted one cycle of treatment. Reduced-fluence 
PDT was selected because full-fluence appears to cause 
more long-term retinal thinning [21]. Other authors have 
used half-fluence PDT with triple therapy with success 
[22].
After the initial treatment cycle, patients were re-exam-
ined within 4–6  weeks. Once deemed stable, follow-up 
was undertaken every 6–8 weeks in year one and every 
8–12  weeks in year two. Retreatment was based on the 
presence of any of the following: subretinal fluid/blood 
on clinical exam, intraretinal or subretinal fluid on opti-
cal coherence tomography (OCT), decrease in vision, late 
leakage on fluorescein angiography, or an occult plaque 
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on indocyanine green angiography. When retreatment 
was necessary, triple therapy was given.
Triple therapy patients with Zx The second consecutive 
series comprised 253 eyes of 214 patients, 127 female and 
87 male. Their ages ranged from 53 to 97, with a mean of 
80 years. One hundred twenty-one eyes (94.1 %) were fol-
lowed for 12 months and 93 eyes (72.4 %) were followed 
for 24 months. Visual acuity ranged from 20/30 to 20/400 
at baseline, with a mean initial LogMAR visual acuity of 
1.00 (20/200). This second cohort was treated with tri-
ple therapy identical to the first. In addition, participants 
were given oral zeaxanthin, 20  mg, daily (Eye Promise 
Zeaxanthin, ZeaVision), for 2 years. Retreatment criteria 
were the same.
The economic model
Incremental and average cost-utility analyses were per-
formed using a Value-Based Medicine® (standardized) 
cost-utility model [23, 24]. Patient time tradeoff utili-
ties, a third party insurer cost-perspective and national, 
average, Medicare Fee Schedule costs (Table 1) were uti-
lized. The base case employed an incremental cost-utility 
analysis comparing triple combination therapy with Zx 
to triple combination therapy without Zx for neovascu-
lar AMD. Average cost-utility analyses compared triple 
therapy with Zx to no treatment and triple therapy to no 
treatment.
Model time frame
A nine-year time frame was used, the mean life expec-
tancy for the average 81-year-old in the combined 
cohorts. A LOCF (last observation carried forward) 
methodology was employed from 25 months to 9 years. 
The base case assumed oral Zx was continued for 9 years.
A theoretical control cohort for both cohorts was cre-
ated using data from Shah and DelPriore [25]. They 
analyzed control cohort visions from six randomized, 
neovascular AMD clinical trials with a Lineweaver-Burke 
model, demonstrating the mean vision associated with 
untreated neovascular AMD correlated with the time 
since onset of CNV. By the ninth year, the mean vision 
associated with untreated neovascular AMD deteriorated 
to 20/640+1 (Table 2).
First‑eye, second‑eye models
The concept of first-eye, second-eye and combined-eye 
models was developed at the Center for Value-Based 
Medicine® based upon primary patient data [23, 24, 26, 
27]. They are based upon observations that vision-related 
quality-of-life most closely correlates with vision in the 
better-seeing eye. The first-eye model indicates the first 
eye is under treatment and the second eye is unaffected 
by the disease, neovascular AMD herein. The second-eye 
model indicates the first eye already has vision loss from 
the untreated disease. As clinicians know, losing vision 
in a second eye in addition to the first is devastating if 
untreated. Thus, the second-eye model yields the great-
est patient value gain with therapy. The combined-eye 
model is simply the weighted average of the first-eye and 
second-eye models. The combined-eye model was used 
for the base case cost-utility analysis herein.
Patient preference‑based comparative effectiveness
Study data were converted to a patient preference-based 
format to quantify quality-of-life using time tradeoff utili-
ties obtained from over 1100 interviews with ophthalmic 
patients [23, 24]. Utilities are often referred to as patient 
preferences since patients can prefer to trade something 
Table 1 Average national medicare costs in 2015 US nominal dollars
CPT current procedural terminology, the interventional classification utilized by Medicare, NA not applicable
a Not included within the Medicare CPT codes
Intervention CPT code Cost per treatment
Visudyne dye for PDT therapy J3396 $1613
Intravitreal bevacizumab, 1.25 mg J9035 $68
Intravitreal dexamethasone, 1 mg J1100 $10
Photodynamic therapy physician fee 67,221 $298
Intravitreal injection of medication 67,028 $106
Fundus photography 92,250 $79
Intravenous fluorescein angiography 92,235 $111
Indocyanine green angiography 92,240 $256
Optical coherence tomography 92,134 $46
Ophthalmological services, medical examination and evaluation 92,004 $151
Ophthalmological services, medical examination and evaluation 92,012 $87
Ophthalmological services, medical examination and treatment 92,014 $126
Eye Promise Zeaxanthina, Zea Vision, 20 mg per day, 1-year cost NA $360
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of value (theoretical time of life) to hypothetically improve 
their health state, or prefer not to trade and keep the same 
health state. Excellent validity [28] and reliability [29] have 
been demonstrated for these utilities. They have been uti-
lized in numerous peer-reviewed papers by the authors 
[26, 27, 30–34] and other researchers [35–37].
Vision utilities range from 1.00 (bilateral vision ≥20/20 
permanently) to 0.00 (death). As vision in the better-see-
ing eye decreases, the associated utility and quality-of-life 
decrease. The lowest vision anchor utility is 0.26, which 
correlates with bilateral no light perception [30]. Our 
vision results were converted to utilities, then to QALYs 
(quality-adjusted life-years). People accrue QALYs as 
they live. The total QALY accrual is calculated by multi-
plying (utility) × (years lived at that utility). For example, 
living at a utility of 0.80 for 3  year accrues 2.40 QALYs 
(0.80 × 3), and so forth.
Using the average life expectancy of 9  years [38], we 
calculated how many QALYs were accrued by the mean 
triple therapy with Zx patient versus the mean triple 
therapy patient. Adverse events included the disutility 
associated with intravitreal injection, predominantly dis-
comfort up to 24 h. The utility of 0.89 associated with this 
condition was obtained from 68 patients in the Center for 
Value-Based Medicine® Time Tradeoff Utility Database, 
a compendium of over 50,000 patient utilities with acqui-
sition approved by the Wills Eye Hospital Institutional 
Review Board. There were no cases of endophthalmitis. 
One vitreous hemorrhage requiring vitrectomy and one 
retinal detachment occurred, both in the triple therapy 
cohort. Nonetheless, the incidences of these adverse 
events were not significant (p = 0.50, Fisher Exact Test), 
and therefore not included in the base case analysis. A 
0.002 QALY loss previously associated with PDT adverse 
event disutilities was used [31].
Cost‑utility (cost‑effectiveness) analysis
The model outcome was $/QALY, or dollars expended 
per QALY gained from the intervention. This is the cost-
utility (cost-effectiveness) ratio (CUR). Per the Panel on 
Cost-Effectiveness in Health and Medicine, all QALY 
accruals and costs were discounted at 3 % annually [39].
Statistics
Statistics comparing ratios of patients with second eye 
progression to neovascular AMD were performed with 
the Chi square test, which was also used to evaluate 
other categorical variables. Linear variables were com-
pared using the Student’s t test. (Microsoft Excel, Belle-
vue, Washington). Significance was presumed to occur at 
p < 0.05.
The SSM Health Care Institutional Review Board 
approved this study (approval number 14-07-0540. It 
adhered to the Helsinki Declaration of 1975, as revised in 
1983. All participants signed an informed consent form. 
A four-year, prospective, randomized, clinical trial com-
paring triple therapy and triple therapy with Zx for treat-
ing neovascular AMD is currently in its third year. See 
Clinical Trials.gov (Identifier: NCT 01527435).
Results
Clinical features
The mean baseline CNV size in the triple therapy cohort 
was 7.0 disc areas (DA) (SD = 3.5, 95 % CI 6.5–7.5) while 
that in the triple therapy with Zx cohort was 7.4 DA 
(SD = 3.5, 95 % CI 6.9–7.9) (p = 0.32) (Fig. 1). CNV size 
ranged from <1 DA to 12 DA. In both cohorts with uni-
lateral neovascular AMD, over 90  % of fellow eyes had 
Age-Related Eye Disease Study, Category 3 AMD [40] 
with drusen >125 μm, typically with pigmentary changes.
The triple therapy cohort, mean visual acuity improved 
from baseline 20/250 to 20/200 at 12 and 24  months 
(Table  2), a mean gain of 6 EDTRS letters (p  <  0.0001). 
Visual acuity was stable or improved in 79 % of eyes after 
1 year and 87 % after 2 years. The mean number of treat-
ment cycles was 2.1 over 1 year and 2.8 over 2 years. Eyes 
had a mean reduction in retinal thickness from 265 mµ 
(SD = 79, 95 % CI 252–278) to 244 mµ (SD = 66, 95 % CI 
233–255), −21 mµ (−8.0 %) microns on OCT, at 2 years 
(p = 0.001) (Table 3).
Triple therapy plus Zx eyes had mean vision improve 
from baseline 20/200 to 20/160 at 12 and 24  months 
(Table 2), an average gain of 7 EDTRS letters (p < 0.0001). 
Eighty-three percent of eyes had stable or improved 
vision at 2  years, 27.5  % gained 15 letters or more on 
EDTRS, and 17 % were worse by 3 or more lines (p = 0.85 
versus triple therapy cohort distribution). Overall, the 
mean number of treatment cycles was 1.6 at 1 year and 
2.1 over 2  years. The addition of Zx reduced the mean 
Table 2 Mean visual acuity in the triple combination ther-
apy with  zeaxanthin, triple combination therapy with-
out zeaxanthin and control cohorts









1 20/200 20/250 20/200
2 20/160 + 2 20/200 + 1 20/250 − 2
3 20/160 + 2 20/200 + 1 20/320 − 2
4 20/160 + 2 20/200 + 1 20/400 − 1
5 20/160 + 2 20/200 + 1 20/500 + 1
6 20/160 + 2 20/200 + 1 20/500 − 1
7 20/160 + 2 20/200 + 1 20/500 − 2
8 20/160 + 2 20/200 + 1 20/500 − 2
9 20/160 + 2 20/200 + 1 20/640 + 1
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treatment cycles by 24 % at 1 year and 32 % over 2 years. 
Eyes had a mean retinal thickness reduction from 287 mµ 
(SD = 70, 95 % CI 274–300) to 232 mµ (SD = 79, 95 % CI 
223–241), a decrease of 55 microns (−19.2 %) on OCT at 
24 months (p < 0.0001) (Table 3). In both cohorts, larger 
baseline lesion size correlated with increased treatment 
cycles (p  <  0.0001) and decreased vision (p  <  0.0001). 
Visual and anatomic results were compared between eyes 
with classic CNV and occult CNV. No statistical differ-
ence between these groups was seen across all parame-
ters analyzed.
The triple therapy cohort had 160 patients with CNV in 
the first eye and drusen in the fellow eye. Overall, 20 fel-
low eyes (12.5 %) developed CNV over 2 years, 12 in year 
one and 8 in year 2. In the triple therapy plus Zx cohort, 
80 people had CNV in the first eye and drusen in the fel-
low eye. Overall, 5 fellow eyes (6.25 %) developed CNV 
over 2 years, 3 in year 1 and two in year 2 (p = 0.03 ver-
sus triple therapy cohort) (Fig. 2; Table 4).
Economic analysis
Patient value gain
QALYs accrued over 9 years by the triple therapy with Zx, 
triple therapy and control cohorts are shown in Table 5. 
The overall QALY gains for the cohorts are shown in 
Table  6. Utilizing the combined-eye model, triple com-
bination therapy with Zx confers an 8.2 % quality-of-life 
(QOL) gain versus no therapy (p  <  0.0001), while tri-
ple therapy confers a 6.0 % QOL gain versus no therapy 
(p < 0.0001) The highest QOL gain of 14.1 % occurs in the 
triple therapy with Zx cohort with the second-eye model.
A comparison of the two treatment cohorts reveals 
adding Zx enhances QOL by 2.5  % over triple therapy 
alone (p  <  0.0001) (Tables  5, 6). This is the incremental 
patient value gain. Sixty-six percent of patients in the 
current study presented with a first-eye model and 34 % 
a second-eye model when calculating the combined-eye 
patient value gain. Nonetheless, each treated second-eye 
patient in the triple therapy with Zx cohort contributed 
2.21× the value contributed by a treated first-eye patient. 
The less favorable, first-eye, vision utility data were taken 
from the Center for Value-Based Medicine Utility Data-
base [23, 24, 26–34].
Costs
The costs associated with therapeutic strategies are 
shown in Table  7. The total discounted Zx cost per 
patient over 9 years was $2887. The total triple combina-
tion therapy with Zx cost per patient for the combined-
eye model was $10,440. It dropped to $8222 when Zx was 
given for only 2 years instead of nine. The cost for triple 
therapy was $9540, intermediate between Zx given for 
2 years and 9 years. The base case cost of $10,440 in the 
triple therapy with Zx cohort was distributed as follows: 
physician: $2521 (24  %), diagnostic testing: $815 (8  %), 
drugs other than Zx: $4176 (40 %), and Zx: $2887 (28 %).
Cost‑utility (cost‑effectiveness)
The base case, combined-eye, incremental CUR 
for the use of triple therapy with Zx referent to 
0 2 4 6 8 10 12 14
3 or more treatment cycles
2 or less treatment cycles
Baseline VA < 20/100
Baseline VA > 20/100
All eyes
Lesion size in disc areas
Baseline Lesion Size 
TTZ TT
Fig. 1 Baseline lesion size and treatment cycles. Baseline lesion size corresponded significantly to number of treatment cycles required and 
decreased visual acuity. TTZ triple combination therapy with zeaxanthin, TT triple combination therapy, VA vision. Baseline VA <20/100 = 20/200 
or worse vision (p < 0.0001 for baseline VA >20/100 versus baseline VA <20/100, as well as for 2 or less treatment cycles versus 3 or more treatment 
cycles)
Table 3 Central foveal thickness as seen on OCT
TT triple combination therapy, TTZ triple combination therapy with zeaxanthin, 















TT 265 244 −21 −8.0 p = 0.001
TTZ 287 232 −55 −19.2 p < 0.0001
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triple therapy alone was $5302/QALY (Table  8). This 
assumed Zx was used for 9  years. The average CUR 
for the use of triple therapy with Zx was $19,962/
QALY, while the average cost-CUR for the use of tri-
ple therapy was $26,574/QALY.
Sensitivity analysis (Table 9)
Sensitivity analysis assesses the variables of least confidence. 
In this instance, it demonstrated the incremental CUR 
for the triple therapy with and without Zx to range from 
(−$8148/QALY) when Zx was used for only the first 2 years 
to $23,892/QALY when Zx was used for 9 years, but had no 
benefit after 2 years. The cost of Zx must rise to $318/month 
for an incremental CUR of $100,000/QALY. The cost of Zx 
must rise to $513/month for a CUR of $158,000/QALY, or 
3× the US Gross Domestic Product per capita.
Comparing our triple therapy with Zx cohort data to 






















Development of CNV in Fellow Eye 
12 months
24 months
Fig. 2 Choroidal neovascularization conversion in the fellow eye. The percentage of patients that converted to CNV in the fellow eye in the current 
study and other studies: Barbazetto et al. [41] for ANCHOR, MARINA and PDT photodynamic therapy with verteporfin, Overall numbers from a meta-
analysis (Wong et al. Ophthalmology 2008;115:1524), AREDS Age-Related Eye Disease Study [19], TT triple combination therapy in current study, 
TTZ triple combination therapy with zeaxanthin in current study (CNV choroidal neovascularization). A 24-month comparison of conversion rates to 
CNV in the fellow eye in the TT and TTZ cohorts showed that zeaxanthin significantly decreased conversion in fellow eyes (p = 0.03). A 24-month 
MARINA and ANCHOR CNV conversion study in the fellow eye revealed a far greater 24-month rate in MARNA/ANCHOR than in our triple combina-
tion therapy cohort (p = 0.6 × 10−6) or the triple combination therapy cohort with zeaxanthin (p = 1.0 × 10−14)
Table 4 Choroidal neovascularization in the fellow eye developing from 0 to 24 months after baseline versus Barbazetto 
et al. [41]
TT triple combination therapy, TTZ triple combination therapy with zeaxanthin, CFT central foveolar thickness
Conversions in current study  
(conversions/fellow eyes with dry AMD)
Conversions-Barbazetto et al. [41]  
(conversions/fellow eyes with dry AMD)
p-value
TT, 12 months 12/160 (20 %) 100/445 (22.5 %) 0.0001
TTZ, 12 months 3/80 (3.75 %) 100/445 (22.5 %) 0.00003
TT, 24 months 20/160 (12.5 %) 151/445 (33.9 %) 0.0000006
TTZ, 24 months 5/80 (6.25 %) 151/445 (33.9 %) 1 × 1.0−14
Table 5 QALY (quality-adjusted life-year) accrual asso-
ciated with  the three cohorts over  9  years (discounted 
at 3 % annually)
TTZ triple therapy with zeaxanthin, TT triple therapy
Combined-eye model = 66 % first-eye model and 34 % second-eye model, 
Zeaxanthin = Zx
Model TTZ cohort TT cohort Control 
cohort [25]
First-eye model 7.202 7.050 6.749
Second-eye model 5.269 5.016 4.616
Combined-eye model 6.546 6.384 6.024
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Barbazetto et al. [41] there is a 2-year absolute risk reduc-
tion of 30.3 % (the 36.6 % incidence of fellow eye CNV in 
ANCHOR/MARINA minus the 6.3 % incidence of CNV 
with our triple therapy with Zx cohort) (p < 1.0 × 10−14). 
The triple therapy cohort also had less CNV conversions 
at 2 years (p = 0.6 × 10−6). The incremental CUR for Zx 
addition drops to (−$5601/QALY) with Barbazetto et al. 
data [41]. The minus CUR indicates that Zx with triple 
therapy dominates triple therapy by conferring more 
patient value for less cost. The average CUR for triple 
therapy with Zx drops to $10,052/QALY.
Discussion
Our case series showed that triple therapy with Zx 
yielded a visual result superior to that of triple therapy 
alone. At the same time, it significantly decreased the 
onset of CNV in the fellow eye. That said, both triple 
therapy with and without Zx are superior to observation.
The series applied a combination of agents to treat sub-
foveal CNV in AMD. Anti-VEGF treatment is the main-
stay in treatment for neovascular AMD. The MARINA 
study [11] was associated with monthly injections of 
ranibizumab. Visual acuity, ophthalmoscopic signs and 
diagnostic studies all showed significant benefits over 
2 years of follow-up in patients with minimally classic or 
occult lesions. The ANCHOR study [10] found ranibi-
zumab therapy more effective than PDT for predomi-
nantly classic, subfoveal CNV. The CATT Study noted 
that ranibizumab and bevacizumab similarly improved 
visual acuity [12]. It is difficult to compare patient value 
gain with those studies since they enrolled patients with a 
mean vision of 20/80, versus 20/200-20/250 in our study. 
There is a greater potential for value gain when CNV 
patients are treated earlier in their course with better 
vision [42].
Ongoing VEGF-inhibitor treatment, however, creates 
patient and healthcare system burdens. The patient bur-
den may actually cause some to stop treatment before 
remission [43]. The incidence of serious ocular and sys-
temic adverse events with anti-VEGF injections is low, 
but rates can increase when therapy is repeatedly applied 
[44]. In addition, VEGF may play a role in the survival 
and maintenance of RPE integrity [45].
PDT leads to selective cytotoxicity of vascular endothe-
lial cells by producing oxidative radicals [46]. But despite 
an early angiographic effect suggesting disappearance 
of CNV, patients experience a mean visual loss of two 
ETDRS lines of vision during the first 6  months after 
treatment [8, 47]. Studies of the angiogenic effect of PDT 
Table 6 QALY and  (percent patient value gains) for  triple 
combination therapy cohorts associated with  zeaxanthin 
use and with no zeaxanthin use
TTZ triple therapy with zeaxanthin, TT triple therapy
Combined-eye model = 66 % first-eye model and 34 % second-eye model, 
Zeaxanthin = Zx
Model TTZ vs. control 
cohort
TT vs. control 
cohort
TTZ vs. TT
First-eye model 0.453 (6.7 %) 0.339 (5.0 %) 0.115 (1.6 %)
Second-eye  
model
0.653 (14.1 %) 0.400 (8.7 %) 0.253 (5.0 %)
Combined-eye 
model
0.521 (8.2 %) 0.359 (6.0 %) 0.162 (2.5 %)
Combined-eye 
model
p < 0.0001 p < 0.0001 p < 0.0001
Table 7 Nine-year costs for zeaxanthin and no zeaxanthin triple therapy (2015 US Real dollars, discounted at 3 % annu-
ally)
Combined-eye model = 66 % 1st-eye model and 34 % 2nd-eye model
TTZ triple combination with zeaxanthin, TT triple combination therapy
Model No zeaxanthin  
treatment  
cohort
Triple combination therapy  
with zeaxanthin (9 years  
of zeaxanthin)
Triple combination therapy 
with zeaxanthin (2 years 
of zeaxanthin)
First-eye, second-eye or combined-eye  
model: the same for all
$9540 $10,440 $8222
Table 8 Cost–utility ratios of triple therapy and triple therapy with zeaxanthin
Model TTZ vs TT TTZ vs. control cohort TT vs. control cohort
Incremental CUR Average CUR Average CUR
First-eye model $7470/QALY $22,958/QALY $28,142/QALY
Second-eye model $3395/QALY $15,926/QALY $23,850/QALY
Combined-eye model $5302/QALY $19,962/QALY $26.574/QALY
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show increased VEGF, VEGF-R and PEDF in eyes [9]. 
This suggests combination therapy with an anti-VEGF 
agent is reasonable.
Corticosteroids stabilize the blood retinal barrier and 
down regulation of inflammation [48]. In addition, they 
have anti-fibrotic and anti-angiogenic activity, the latter 
which can last for 3 months [48].
Multiple studies have suggested combination ther-
apy addresses the mechanisms of disease progression. 
Combination PDT and ranibizumab therapy in AMD 
patients with CNV has been associated with CNV 
occlusion, reduced retinal edema and improved vision 
[49]. Wan and colleagues [50] treated 174 eyes with 
PDT, then intravitreal bevacizumab 30 days later. Over 
a mean 10  months, patients received an average of 3.0 
bevacizumab injections and 1.4 PDT treatments. After 
stabilization, the mean treatment-free interval was 
193 days, and 52 % of patients required no post-induc-
tion retreatment. Visual acuity improved at 2, 4, and 
6 months.
In a number of population-based studies, lutein and 
Zx levels have been inversely associated with the risk 
of AMD. The POLA study [51] found high total plasma 
lutein and Zx reduced the risk of AMD by 79 %, with a 
particularly strong association between Zx and AMD. 
Subjects with high levels of plasma Zx had a 93 % reduced 
risk of AMD vs. those with low levels. Similar studies in 
China [52] and the UK [6], also showed Zx had a greater 
positive influence. In the UK study, a 50 % reduced risk of 
AMD was noted in people with high plasma Zx.
Table 9 Sensitivity analysis
A negative cost-utility ratio indicates that neovascular age-related macular degeneration triple therapy with zeaxanthin provides greater patient value than triple 
therapy without zeaxanthin and is also less expensive than triple therapy without zeaxanthin.) (Dollars are 2015 US real dollars discounted at 3 % annually. QALYs are 
discounted at 3 % annually.
Incremental cost–utility of TTZ vs. TT cohorts, combined-eye model
QALY quality-adjusted life-year, $/QALY dollars expended per QALY gained, PDT photodynamic therapy with verteporfin, GDP gross domestic product, TTZ triple 
combination therapy with zeaxanthin, TT triple combination therapy, Zx zeaxanthin, WHO World Health Organization





Therapeutic changes in the TTZ cohort
 Base case
  Zx daily for 9 years in the triple therapy with Zx cohort $859 0.162 $5302
  Zx daily for 2 years only in the triple therapy with Zx cohort (−$1318) 0.162 (−$8148)
  Two additional treatments: bevacizumab, PDT and dexamethasone, years 3–9 in  
both cohorts
$859 0.162 $5,312
  Costs in both cohorts are doubled $1718 0.162 $10,623
  Zx cost over 9 years is doubled from $30/month to $60/month $3746 0.162 $23,154
  Zx cost/month for cost-utility ratio of $50,000/QALY $150 0.162 0 $50,000
  Zx cost/month for cost-utility ratio of $100,000/QALY $318 0.162 $100,000
  Zx cost/month for cost-utility ratio of $158,000/QALY(WHO upper limit for cost-effective-
ness = 3× GDP per capita)
$513 0.162 $158,000
Altering patient value gains associated with TTZ
 Doubling patient value gains in both cohorts $859 0.324 $2,656
 Halving the patient value gain from Zx $859 0.081 $10,623
 Loss of Zx benefit after year 2 with 2 years of Zx therapy in the TTZ cohort (−$1318) 0.036 (−$36,665)
 Loss of Zx benefit after year 2, with 9 years of Zx therapy in the TTZ cohort $859 0.036 $23,892
 Zx incremental QALY gain for $50,000/QALY $859 0.017 $50,000
 Zx incremental QALY gain for $100,000/QALY $859 0.0086 $100,000
 Zx incremental QALY gain required for $158,000/QALY (WHO upper limit for cost-effective-
ness = 3× 2015 US GDP per capita)
$859 0.0054 $158,000
Integrating the therapeutic QALY gain and costs saved by TTZ decreasing the onset of neovascular AMD in the fellow eye: combined-eye model
 Incremental cost-utility
  Zx daily for 9 years in the TTZ cohort vs. TT cohort—assumes that TTZ yields an absolute risk 
reduction of CNV in the 2nd eye of 30.3 %
(−$2291) 0.362 (−$6332)
 Average cost-utility
  Zx daily for 9 years in the TTZ cohort vs. TT cohort: assumes TTZ reduces the absolute risk 
reduction of CNV in the 2nd eye by 30.3 %
7249 0.7212 $10,052
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The reasons for Zx benefit are elusive. Evidence sug-
gests a role for Zx as a filter to blue light, preventing it 
from entering the outer retina [53]. Short wavelength 
blue light contains energy, and filtering this light 
may limit metabolic insult. Zeaxanthin also serves 
as an antioxidant; it consumes singlet oxygen and 
may quench free radicals generated by normal retinal 
metabolism. Increased levels of Zx also inhibit VEGF 
levels [53, 54].
We recognize the limitations of consecutive case series 
versus a randomized controlled trial. However, our infor-
mation suggests triple therapy with bevacizumab, dexa-
methasone and PDT is a viable option for wet AMD, and 
that oral Zx enhances that benefit. The percentage of sta-
ble or improved eyes in both of our cohorts (more than 
80  %) is very encouraging. Oral Zx may also provide a 
protective benefit for the fellow eye. This requires further 
study, but suggests protection against CNV development 
could considerably preserve vision.
While some clinicians believe monthly injections of 
anti-VEGF drugs are not necessary with monotherapy, 
studies still show less visual acuity gains with less fre-
quent dosing [12, 55]. Subjects receiving triple ther-




The use of oral Zx with triple combination therapy is very 
cost-effective, with an incremental cost-utility ratio (CUR) 
of $5302/QALY. No formal US formal cost-effective-
ness criteria exist, but a CUR <$100,000/QALY is often 
thought cost-effective [24]. World Health Organization 
[56] criteria state a CUR <1x Gross Domestic Product 
(GDP) per capita (~US $53,000 [57]) is very cost-effec-
tive, while a CUR <3× GDP per capita (~US $158,000) is 
cost-effective. The National Institute for Health and Care 
Excellence (NICE) in the UK suggests a CUR <£20,000/
QALY (~US $29,750) is cost-effective, although £30,000/
QALY (~US $44,326) is sometimes allowed [58]. By any of 
the above criteria, triple combination therapy for neovas-
cular AMD appears to be very cost-effective. The addition 
of oral Zx is more cost-effective yet. GDP per capita data 
suggest adding Zx to triple therapy would be cost-effec-
tive in 127 of the world’s 198 countries, even if healthcare 
costs were similar to the US [57].
Conclusions
In summary, neovascular AMD triple therapy is com-
paratively effective and cost-effective. It requires con-
siderably less treatment than needed with monotherapy. 
Adding oral Zx appears to further reduce the treatment 
cycles required, and possibly reduce fellow eye CNV 
development. Nonetheless, the results of a randomized 
trial will be critically important.
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